Table 1.
Baseline demographics and disease characteristics of the study population.
| Total | SOF + DCV | SOF + DCV + RBV | SOF + RBV | SOF + P-R | Not Known | ||
|---|---|---|---|---|---|---|---|
| Number of patients (F/M) | 45 | 7 | 16 | 12 | 9 | 1 | |
| (7/38) | (0/7) | (1/15) | (2/10) | (4/5) | (0/1) | ||
|
Median Age, years (range) |
56 | 56 | 56 | 57 | 56 | n.a. | |
| (42–69) | (49–63) | (42–63) | (52–69) | (47–66) | |||
|
HCV RNA (Log10 IU/mL) Median (Min–Max) |
5.3 | 5.0 | 5.2 | 5.5 | 5.9 | 5.4 | |
| (1.1–7.0) | (1.1–7.0) | (4.0–6.8) | (3.8–6.7) | (3.2–6.7) | |||
|
HIV positive patients (F/M) |
3 | 0 | 1 | 2 | 0 | 0 | |
| (0/3) | (0/0) | (0/1) | (0/2) | (0/0) | (0/0) | ||
|
Number of patients without cirrhosis * (F/M) |
9 | 2 | 3 | 3 | 1 | n.a. | |
| (0/9) | (0/2) | (0/3) | (0/3) | (0/1) | |||
|
Number of patients with cirrhosis * (F/M) |
35 | 5 | 13 | 9 | 8 | n.a. | |
| (7/28) | (0/5) | (1/12) | (2/7) | (4/4) | |||
| Prior pegIFN experience |
Treatment–naive (F/M) |
26 | 5 | 8 | 6 | 6 | 1 |
| (3/23) | (0/5) | (0/8) | (1/5) | (2/4) | (0/1) | ||
|
Treatment–experienced (F/M) |
19 | 2 | 8 | 6 | 3 | 0 | |
| (4/15) | (0/2) | (1/7) | (1/5) | (2/1) | (0/0) | ||
HCV = hepatitis C virus; HIV = human immunodeficiency virus; SOF = sofosbuvir; DCV = daclatasvir; RBV = ribavirin; P-R = pegylated interferon (pegIFN) + ribavirin (RBV); n.a. = not available; F = female; M = male; HIV = human immunodeficiency virus. * Based on clinical or histological features or with non-invasive assessment by transient elastography (stiffness > 14 KPa).